Induction of a SALL4-dependency for targeted cancer therapy

Junyu Yang, Chong Gao, Miao Liu, Zhiyuan Chen, Yao‐Chung Liu, Junsu Kwon, Jun Qi, Xi Tian, Alicia Stein, Yanjing Liu, Nikki R. Kong, Yue Wu, Shenyi Yin, Jianzhong Xi, Hongbo R. Luo, Leslie E. Silberstein, Julie A.i. Thoms, Ashwin Unnikrishnan, John E. Pimanda, Daniel G. Tenen, Li ChaibioRxiv 2020 · DOI

TL;DR

This paper introduces a novel strategy to expand the reach of targeted cancer therapies. By pharmacologically inducing the expression of the oncofetal protein SALL4 in cancer cells that normally lack it, researchers can create a dependency on SALL4, making these cells susceptible to SALL4-targeting drugs. This approach, demonstrated with hypomethylating agents and a histone deacetylase inhibitor, offers a promising way to broaden the applicability of targeted therapies.

What Problem Does This Paper Address?

Targeted cancer therapies, which focus on specific molecular vulnerabilities in cancer cells, have revolutionized treatment. However, their effectiveness is often limited to a subset of patients whose tumors express the specific target. The oncofetal protein SALL4 is a prime example: it's crucial for the survival of many cancer cells and a promising therapeutic target, but it's only expressed in a fraction of cancer patients. This leaves a significant portion of patients without access to SALL4-based treatments. The challenge, therefore, is to find ways to make SALL4-negative cancer cells susceptible to SALL4-targeting therapies.

Methods

The study employed a multi-pronged approach:

  • Cell Culture and Transfection: Standard cell culture techniques were used with various cancer cell lines (lung, liver, leukemia). SALL4 was introduced into SALL4-negative cells using retroviral transduction. RNA interference (shRNA) was used to knock down SALL4 expression.
  • Drug Treatment: Hypomethylating agents like 5-aza-2'-deoxycytidine (DAC) and histone deacetylase inhibitors like Entinostat (ENT) were used to modulate SALL4 expression and cell viability.
  • Molecular Biology Techniques:
    • Western Blotting: Used to detect and quantify protein levels of SALL4 and beta-actin (as a loading control).
  • Quantitative Real-Time PCR (qPCR): Used to measure mRNA levels of SALL4 and microRNA miR-205, with GAPDH or U6 as normalization controls.
  • RNA Sequencing: Performed to identify genes differentially expressed upon SALL4 overexpression.
  • ChIP-qPCR: Used to investigate epigenetic modifications (H3K27ac) at the miR-205 promoter region.
  • Dual-Luciferase Reporter Assay: Employed to confirm direct targeting of SALL4 mRNA by miR-205.
  • Bisulfite Sequencing and Pyrosequencing: Used to assess DNA methylation status at the SALL4 exon 1 region.
  • In Vivo Studies: Xenograft mouse models were used to evaluate the efficacy of the combined DAC and ENT treatment strategy on tumor growth.
  • Cell Viability and Apoptosis Assays: CCK-8 assays were used to measure cell viability, and flow cytometry with Annexin V/propidium iodide staining was used to assess apoptosis.

Datasets

The study utilized publicly available datasets for analysis:

  • CCLE Database: Cancer Cell Line Encyclopedia, used to analyze SALL4 expression in relation to DNA methylation across various cancer cell lines.
  • TCGA Database: The Cancer Genome Atlas, used to examine SALL4 expression in primary tumor samples from different cancer types in correlation with DNA methylation.
  • GSE5816: A publicly available RNA-seq dataset used to assess the effect of DAC treatment on SALL4 expression in H1299 cells.

No new benchmarks or datasets were introduced by the authors.

Key Insights and Ideas

  • Inducible Dependency: The core insight is that SALL4-negative cancer cells can be "made addicted" to SALL4. By introducing SALL4, these cells become critically dependent on its presence for survival, creating a vulnerability that can be exploited.
  • Pharmacological Reactivation: Hypomethylating agents like DAC can effectively "switch on" SALL4 expression in cells where it's silenced due to DNA methylation. This provides a non-genetic way to induce SALL4.
  • miR-205 as a Mediator: Entinostat (ENT), a histone deacetylase inhibitor, doesn't directly inhibit SALL4 protein but rather upregulates miR-205, which then post-transcriptionally represses SALL4. This reveals a novel regulatory pathway.
  • Synergistic Combination Therapy: The sequential treatment of DAC followed by ENT shows significant promise. DAC primes SALL4-negative cells by upregulating SALL4, making them highly sensitive to ENT, which then leverages the induced SALL4 dependency.
  • Expanding Targeted Therapy Scope: This work provides a proof-of-concept for a broader strategy: inducing a target in cancer cells that don't naturally express it, thereby expanding the patient population that can benefit from targeted therapies.

Key Results

  • SALL4 Induction: DAC treatment significantly increased SALL4 mRNA and protein levels in SALL4-negative cancer cell lines (H1299, SNU387) and primary cells, correlating with decreased DNA methylation at the SALL4 exon 1 locus.
  • Engineered Dependency: Exogenous expression of SALL4 in H1299 cells rendered them sensitive to SALL4 knockdown, leading to reduced viability and increased apoptosis, mirroring the phenotype in endogenous SALL4-expressing cells.
  • ENT's Mechanism: ENT treatment led to decreased SALL4 protein and mRNA levels in H661 cells, and this effect was rescued by SALL4 overexpression. Further analysis revealed that ENT upregulated miR-205, which directly targeted SALL4 mRNA.
  • Combination Therapy Efficacy: In cell culture, DAC pre-treatment sensitized SALL4-negative H1299 cells to ENT, significantly reducing their IC50. In vivo, the combination of DAC and ENT significantly suppressed tumor growth in H1299 xenograft models compared to either drug alone or vehicle.
  • Clinical Relevance: The study notes that combinations of hypomethylating agents and HDAC inhibitors (like DAC and ENT) have shown promise in clinical trials for various cancers, suggesting a potential translational impact.

Limitations and Future Work

  • Mechanism of ENT-induced miR-205 Upregulation: While the study shows ENT upregulates miR-205 and that this is linked to SALL4 inhibition, the precise epigenetic mechanism by which ENT affects miR-205 expression (beyond H3K27ac at the promoter) is not fully elucidated.
  • Broader Applicability: While demonstrated in several cell lines, further studies are needed to confirm the efficacy of this strategy across a wider range of SALL4-negative cancers.
  • Clinical Translation: The study proposes investigating this approach in cancer patients receiving HMA and ENT, indicating a clear path for future clinical research.
  • Off-target Effects: The potential for off-target effects of DAC and ENT, especially in combination, warrants further investigation in preclinical and clinical settings.

Summary updated

Abstract

Abstract Oncofetal protein SALL4 is critical for tumor cell survival, making it a promising target in cancer therapy. However, it is detectable only in a subset of cancer patients, which limits the therapeutic impact of a SALL4 targeted therapy. Here we report that SALL4 can be activated and/or upregulated pharmacologically by hypomethylating agents, such as 5-Aza-2’-deoxycytidine (DAC), which are used clinically, and that SALL4 negative cancer cells become SALL4 dependent following exogenous expression of SALL4. In addition, the histone deacetylase inhibitor Entinostat (ENT) negatively regulates SALL4 expression by upregulating miR-205. Both ENT and miR-205 treatment induced cell apoptosis, rescuable by SALL4 expression or miR-205 inhibition. Finally, DAC pre-treatment sensitizes SALL4 negative cancer cell lines to ENT both in culture and in vivo by upregulating SALL4. Overall, we propose a framework whereby the scope of targeted therapy can be expanded by sensitizing cancer cells to treatment by target induction and engineered dependency. Significance This proof of concept study demonstrates that targeted cancer therapy can be achieved by inducing a targetable gene establishing a survival-dependency for cancer cells. For SALL4, sequential treatment of DAC and ENT could expand the scope of SALL4 targeted cancer therapy.
BibTeX
@misc{yang2020induction,
  author = {Junyu Yang and Chong Gao and Miao Liu and Zhiyuan Chen and Yao‐Chung Liu and Junsu Kwon and Jun Qi and Xi Tian and Alicia Stein and Yanjing Liu and Nikki R. Kong and Yue Wu and Shenyi Yin and Jianzhong Xi and Hongbo R. Luo and Leslie E. Silberstein and Julie A.I. Thoms and Ashwin Unnikrishnan and John E. Pimanda and Daniel G. Tenen and Li Chai},
  title = {{Induction of a SALL4-dependency for targeted cancer therapy}},
  year = {2020},
  doi = {10.1101/2020.07.10.197434},
  howpublished = {bioRxiv},
}
Figure